Chiltern: The CRO Future Is Mid-Sized
In remaining private, and neither aspiring to become--or to merge into--a global organization, nor interested in being a specialty CRO, Chiltern is bucking the trend of an industry which over the last decade has seen considerable consolidation at the top accompanied by a proliferation of much smaller niche players. The company's strategy of balancing customer-focused, cost efficient services with the ability to run pan-European/US clinical trials seems well-aimed to capture the business of the emerging and mid-size pharmaceutical companies that will likely be the most prolific source of new innovative drugs over the next decade.
You may also be interested in...
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.
Ambrx is using its technology for engineering proteins with novel amino acids--beyond the 20 that oocur in nature--to enhance the properties of proteins whose potential therapeutic uses, as well as liabilities, are known.